ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 262 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,542,948 | +41.8% | 457,915 | +63.0% | 0.00% | 0.0% |
| Q2 2023 | $6,729,759 | -77.4% | 280,992 | -82.3% | 0.00% | -75.0% |
| Q1 2023 | $29,825,764 | +89308.4% | 1,584,784 | -24.4% | 0.00% | 0.0% |
| Q4 2022 | $33,359 | -99.9% | 2,095,491 | +12.7% | 0.00% | 0.0% |
| Q3 2022 | $30,413,000 | +13.2% | 1,858,961 | -2.5% | 0.00% | 0.0% |
| Q2 2022 | $26,866,000 | -52.0% | 1,906,720 | -17.5% | 0.00% | -42.9% |
| Q1 2022 | $55,957,000 | +8.9% | 2,310,355 | +4.9% | 0.01% | +16.7% |
| Q4 2021 | $51,399,000 | +33.6% | 2,202,176 | -4.9% | 0.01% | +20.0% |
| Q3 2021 | $38,462,000 | -33.8% | 2,315,616 | -2.8% | 0.01% | -28.6% |
| Q2 2021 | $58,088,000 | +60.6% | 2,381,568 | +69.9% | 0.01% | +40.0% |
| Q1 2021 | $36,164,000 | -28.2% | 1,401,713 | +48.8% | 0.01% | -28.6% |
| Q4 2020 | $50,349,000 | +43.2% | 941,810 | +8.3% | 0.01% | +16.7% |
| Q3 2020 | $35,149,000 | -32.6% | 869,842 | -19.2% | 0.01% | -40.0% |
| Q2 2020 | $52,180,000 | +12.5% | 1,076,555 | -1.9% | 0.01% | -9.1% |
| Q1 2020 | $46,362,000 | -3.4% | 1,097,306 | -2.2% | 0.01% | +22.2% |
| Q4 2019 | $48,009,000 | +21.6% | 1,122,216 | +2.3% | 0.01% | +12.5% |
| Q3 2019 | $39,485,000 | +27.2% | 1,097,126 | -6.6% | 0.01% | +33.3% |
| Q2 2019 | $31,050,000 | +43.3% | 1,174,763 | +45.5% | 0.01% | +50.0% |
| Q1 2019 | $21,674,000 | +63.2% | 807,216 | -1.7% | 0.00% | +33.3% |
| Q4 2018 | $13,279,000 | -21.1% | 821,171 | +1.3% | 0.00% | 0.0% |
| Q3 2018 | $16,836,000 | +121.2% | 810,987 | +62.7% | 0.00% | +50.0% |
| Q2 2018 | $7,610,000 | -82.4% | 498,339 | -74.1% | 0.00% | -77.8% |
| Q1 2018 | $43,312,000 | -25.8% | 1,927,596 | -0.6% | 0.01% | -25.0% |
| Q4 2017 | $58,394,000 | -19.0% | 1,939,380 | +3.2% | 0.01% | -25.0% |
| Q3 2017 | $72,128,000 | +37.3% | 1,879,824 | -0.2% | 0.02% | +33.3% |
| Q2 2017 | $52,521,000 | -14.5% | 1,883,166 | +5.4% | 0.01% | -14.3% |
| Q1 2017 | $61,417,000 | +3.4% | 1,786,424 | -13.3% | 0.01% | 0.0% |
| Q4 2016 | $59,405,000 | +20.1% | 2,059,832 | +32.5% | 0.01% | +16.7% |
| Q3 2016 | $49,453,000 | +69.9% | 1,554,619 | +73.3% | 0.01% | +71.4% |
| Q2 2016 | $29,113,000 | +0.7% | 896,848 | -13.3% | 0.01% | 0.0% |
| Q1 2016 | $28,920,000 | -19.6% | 1,034,322 | +2.5% | 0.01% | -22.2% |
| Q4 2015 | $35,982,000 | +7.1% | 1,009,336 | -0.7% | 0.01% | 0.0% |
| Q3 2015 | $33,605,000 | -30.5% | 1,016,149 | -12.0% | 0.01% | -18.2% |
| Q2 2015 | $48,381,000 | +9.2% | 1,155,244 | -15.0% | 0.01% | +10.0% |
| Q1 2015 | $44,311,000 | -6.6% | 1,359,688 | -9.0% | 0.01% | -9.1% |
| Q4 2014 | $47,463,000 | +100.2% | 1,494,897 | +56.1% | 0.01% | +83.3% |
| Q3 2014 | $23,707,000 | +10.5% | 957,478 | +0.8% | 0.01% | +20.0% |
| Q2 2014 | $21,457,000 | +4.8% | 949,809 | +12.8% | 0.01% | -16.7% |
| Q1 2014 | $20,482,000 | -0.1% | 841,857 | +2.6% | 0.01% | 0.0% |
| Q4 2013 | $20,496,000 | -16.4% | 820,199 | -8.1% | 0.01% | -14.3% |
| Q3 2013 | $24,509,000 | +52.1% | 892,197 | +0.5% | 0.01% | +40.0% |
| Q2 2013 | $16,109,000 | – | 887,532 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |